W. Heim

发表

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Nicholas Iannotti, Taral Patel, Thomas J. Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumor cells.

R. Connor, J. Blom, E. Perlin, 1980, International journal of radiation oncology, biology, physics.

Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004 .

Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.

G. Wampler, W. Heim, N. Ellison, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3‐times‐daily regimen to treat patients with recurrent metastatic breast cancer

G. Hortobagyi, D. Booser, W. Heim, 2010, Cancer.

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

T. Lynch, Martin R. Weber, W. Heim, 2007 .

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

R. Ozols, P. O'dwyer, P. Flynn, 2004, Cancer Chemotherapy and Pharmacology.

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

J. Berlin, J. Hainsworth, F. Kabbinavar, 2005, Journal of surgical oncology.

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

J. Hecht, J. Hecht, W. Heim, 2010, Clinical colorectal cancer.

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

A. Benson, H. Lenz, J. Marshall, 2008, Clinical Cancer Research.

A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study.

G. Wampler, W. Heim, H. Brereton, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective randomized comparison of protracted infusional 5‐fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid‐atlantic oncology program study

G. Wampler, W. Heim, J. Lokich, 1991, Cancer.

Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial.

T. Lynch, R. Hermann, W. Heim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, The New England journal of medicine.

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

J. Hecht, W. Heim, M. Mo, 2010, Clinical colorectal cancer.

Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation.

J. Berlin, J. Hainsworth, F. Kabbinavar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.